Skip to content

Aerobic Training in Patients With Congenital Myopathies

Aerobic Training in Patients With Congenital Myopathies

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02020187
Enrollment
16
Registered
2013-12-24
Start date
2013-09-30
Completion date
2014-11-30
Last updated
2015-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Myopathy

Keywords

Congenital myopathy, Exercise

Brief summary

Congenital myopathies are clinical and genetic heterogeneous disorders characterized by skeletal muscle weakness. Most patients experience muscle weakness and fatigue throughout their life. However, progression of symptoms is rare. There are no specific treatments for congenital myopathies. Training has been shown to benefit several other muscle diseases with weakness, but the defect in congenital myopathies involves contractile proteins of the sarcomere, why the effect of training is uncertain in these conditions. The investigators will therefore investigate the effect cycle-ergometer training for 30 minutes, three times weakly, for ten weeks in 15 patients with congenital myopathy. Another 5-10 congenital myopathy patients, who do not train, will serve as controls for the trained patients. The study starts and ends with a test day, where efficacy based on VO2max, performance in functional tests and a questionnaire will be assessed.

Detailed description

10 weeks of cycle-ergometer training at home. Intensity at 70% of maximal VO2,max.

Interventions

OTHERExercise on a cycle-ergometer

Home training on an ergometer-cycle 30 minutes every other day or at least three times a week. Subject will exercise in a pulse interval corresponding to 70% of their maximal VO2.

Sponsors

Rigshospitalet, Denmark
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Danish patients with gene verified congenital myopathy

Exclusion criteria

* Patients who are to week to train at a cycle-ergometer for 10 weeks * Patients who have other health issues, which can disturb the interpretation of the efficacy

Design outcomes

Primary

MeasureTime frameDescription
Efficacy based on VO2,max10 weeksDifference in VO2,max from baseline to end of intervention.

Secondary

MeasureTime frameDescription
Intensity in maximal Watt10 weeksChanges in the maximal intensity (watt) from baseline VO2,max test to after the intervention.
6 minute walk test10 weeksChanges in the walking distance from baseline to after the intervention.
SF-36 questionnaire10 weeksChanges in SF-36 questionnaire from baseline to after the intervention.
Level of Creatine Kinase10 weeksMarker for exercise-induced muscle damage. Taken week 0, 3 and 10.
A timed 14-step-stair-test10 weeksChanges in time from baseline to after the intervention.
Dynamometry10 weeksChanges in external force production from baseline to after the intervention. Dynamometry measurements are done at hip flexion, dorsal foot flexion, plantar foot flexion, knee flexion, knee extension and elbow flexion.
A timed five-repetitions-sit-to-stand-test10 weeksChanges in time from baseline to after the intervention.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026